The weeks surrounding whelping are not a transition. They are a physiological rupture. Progesterone, which has governed the entire architecture of canine pregnancy, does not taper at parturition. It collapses. The corpus luteum, sole source of that hormone throughout gestation in dogs, withdraws its support in a matter of days, and the dam's endocrine system must reconstitute itself from the inside out while simultaneously sustaining a litter, managing the mechanical aftermath of delivery, and mounting a lactational demand that places pressure on every organ system she possesses. Breeders who have watched a dam in the days after whelping understand this intuitively. The science confirms what they observe.

Seven peer-reviewed investigations form the evidentiary foundation of this article. Their findings are presented as the authors reported them, without extrapolation beyond what the data support, and with full transparency about the gaps that remain. The gaps are real. They are stated plainly. A cannabinoid company that does not tell you where the evidence ends is not a company that has read the evidence.

The Hormonal Architecture of Canine Pregnancy

Hinderer and colleagues, writing in Animals in 2021, tracked progesterone concentrations across 123 pregnant dogs representing multiple breeds and whelping conditions.^[1] The finding that distinguishes dogs from most other domestic species is not subtle: the corpus luteum is the sole source of progesterone throughout the entire gestational period. There is no placental contribution, no secondary hormonal support, no redundancy in the system. When the corpus luteum withdraws, progesterone falls precipitously, and that fall is the signal that initiates parturition. The investigators also documented that puppies delivered by caesarean section exhibited significantly elevated cortisol concentrations compared to those born through natural delivery, a finding with direct implications for neonatal stress physiology and the immune priming that occurs in the first hours of life.

Sahraei and colleagues, publishing in Veterinary Medicine and Science in 2024, characterized the biochemical composition of canine and feline foetal fluids across gestational days 20 through 60.^[2] Glucose, creatinine, liver enzymes, and reproductive hormones all shifted in measurable patterns as gestation progressed, each shift reflecting the metabolic demands placed on the developing foetus and the placental interface that sustains it. What these two studies together establish is not merely a hormonal timeline. They establish the physiological context into which any discussion of cannabinoid administration must be placed. The postpartum dam is not simply a dog that has recently given birth. She is an organism in acute hormonal transition, with an immune system recalibrating, joints bearing the mechanical aftermath of pregnancy, and a lactational demand that has not yet reached its peak.

The Endocannabinoid System in Canine Joint and Immune Tissue

Before any discussion of cannabinoid administration is meaningful, a foundational question must be answered: does the canine body possess the receptor architecture necessary to respond to exogenous cannabinoids? Two independent research groups have answered that question, and their findings are unequivocal.

Zamith Cunha and colleagues at the University of Bologna, publishing in Animals in 2023, harvested synovial membrane tissue from the hip and stifle joints of seven middle-aged dogs of various breeds, none of whom exhibited overt signs of osteoarthritis at the time of tissue collection.^[7] Using Western blot analysis and quantitative immunofluorescence, the investigators confirmed the presence of CB1R, CB2R, and GPR55 in the synoviocytes of all seven animals. CB2R and GPR55 showed moderate to bright expression in fibroblast-like synoviocytes, macrophage-like synoviocytes, neutrophils, and vascular endothelial cells. The authors concluded that the endocannabinoid system is structurally present in canine joint tissue and represents a plausible therapeutic target for cannabinoid-based interventions in arthropathies.

The investigators also noted that THCa, the acidic precursor to THC present in full spectrum hemp products, has been shown to act as an orthosteric CB1R agonist in vivo, reducing inflammatory cell infiltration, synovial hyperplasia, and cartilage damage in collagen-induced arthritis models. Beta-caryophyllene, a terpene present in full spectrum cannabis extracts, was identified as a CB2R agonist with anti-inflammatory properties. GPR55 antagonism by CBD was confirmed to reduce proinflammatory cytokine secretion and immune cell migration. These are not incidental findings. They describe the precise molecular mechanisms through which the cannabinoids present in VetsGrade full spectrum products interact with canine joint tissue, documented by investigators with no commercial relationship to the cannabinoid industry.

Brown and colleagues, publishing in Veterinary Immunology and Immunopathology in 2023, examined cannabinoid receptor expression in the peripheral blood mononuclear cells and spleen of 14 healthy dogs.^[4] Using flow cytometry, Western blot, and quantitative RT-PCR, the investigators found that CNR2, the gene encoding CB2R, was expressed in canine blood at approximately 120-fold higher levels than CNR1, the gene encoding CB1R. The authors also found that cannabinoid-mediated cytokine suppression in canine immune cells was vehicle-dependent, a methodological observation with direct relevance to formulation decisions in veterinary cannabinoid products. The carrier matters. The extraction method matters. The vehicle through which cannabinoids reach the receptor is not a secondary consideration.

What Investigators Found About Cannabinoids and Canine Inflammation

Gugliandolo and colleagues, publishing in Veterinary Sciences in 2021, conducted an ex vivo investigation using whole blood drawn from six healthy German Shepherds.^[3] Blood samples were stimulated with lipopolysaccharide to induce an inflammatory response, then treated with CBD at concentrations of 50 and 100 micrograms per milliliter. The investigators measured interleukin-6, tumor necrosis factor-alpha, nuclear factor kappa B, and cyclooxygenase-2 as markers of inflammatory activity. CBD at both concentrations produced measurable reductions in all four markers in the LPS-stimulated canine blood samples. Interleukin-10, an anti-inflammatory cytokine, was not significantly altered. The authors concluded that CBD exerts anti-inflammatory effects in canine immune cells through established molecular pathways, and that these effects are observable at concentrations achievable through standard supplementation protocols.

Long-Term Safety: What Investigators Found Across One Billion Administrations

Bookout and colleagues, publishing in Frontiers in Veterinary Science in 2024, conducted a 90-day controlled safety study in 32 healthy beagles.^[6] Animals received CBD alone, CBD combined with CBG, or CBD combined with CBDA at a dose of 5 milligrams per kilogram of body weight per day. All three treatment groups completed the study without serious adverse events. Transient elevations in alkaline phosphatase were observed in the CBD group but were not considered clinically significant by the investigators and returned to baseline values over the course of the study. The investigators also analyzed pharmacovigilance data from the National Animal Supplement Council Adverse Event Reporting System, covering the period from 2010 through 2023. Across more than 1.077 billion total cannabinoid administrations to companion animals, the recorded adverse event rate was 2.19 events per million administrations. The serious adverse event rate was 0.01 per million administrations. Full spectrum products recorded an adverse event rate of 2.83 per million administrations, statistically comparable to broad spectrum formulations. A consumer survey component of the study found that 45.3 percent of owners reported zero side effects across the supplementation period.

These numbers deserve to be read slowly. One billion administrations is not a sample. It is a pharmacovigilance record of a scale that most pharmaceutical categories never accumulate, and the adverse event rate it produced is lower than the rate associated with many supplements that carry no regulatory scrutiny whatsoever. The authors concluded that daily cannabinoid administration does not pose a significant safety risk to healthy dogs when administered at evidence-informed doses, a conclusion grounded in data, not in the commercial interest of the companies whose products generated it.

The Honest Conversation About Pregnancy and Lactation

This section requires precision, and it will receive it. Monfort and colleagues, publishing in Frontiers in Pharmacology in 2022, conducted a comprehensive review of cannabinoid pharmacokinetics during pregnancy and breastfeeding across animal and human populations.^[5] Their findings on placental transfer and lactational persistence are unambiguous and must be stated plainly. THC crosses the placental barrier. It accumulates in fetal tissue at concentrations influenced by the lower pH of fetal serum relative to maternal blood, a physiological gradient that draws lipophilic molecules toward the fetal compartment with a consistency that does not depend on dose or frequency of maternal exposure. THC-COOH, the primary metabolite of THC, was detectable in pregnant urine at concentrations ranging from 3.9 to 348.1 nanograms per milliliter for up to 14 weeks following last exposure.

In breast milk, THC concentrations ranged from 1.0 to 420 nanograms per milliliter, with CBD concentrations ranging from 0.4 to 7.1 nanograms per milliliter. Cannabinoids were detectable in breast milk for six or more weeks after last maternal exposure. The authors noted that cannabinoid concentrations in breast milk were at least twice those found in maternal plasma, a consequence of the lipophilic nature of cannabinoids and the fat content of milk. VetsGrade full spectrum solventless hemp products contain CBD, CBG, CBDa, THCa, and trace THC. THCa is the acidic precursor to THC. These are not isolated CBD products. The pharmacokinetic data reported by Monfort and colleagues applies to the cannabinoid profile present in VetsGrade full spectrum formulations, and any company that does not tell you this has not read the paper or has chosen not to share it.

The postpartum dam who has completed nursing, or the breeding dog between reproductive cycles, presents a different risk profile than the pregnant or lactating animal. The safety data from Bookout and colleagues, and the receptor expression data from Zamith Cunha and Brown and their respective teams, speak directly to that population. The distinction matters, and it is one that VetsGrade makes explicitly, because the alternative is to pretend the distinction does not exist.

Frequently Asked Questions